Vyleesi Appetite & Cravings Changes: What the Clinical Evidence Shows

Why Bremelanotide Affects Appetite at All

Bremelanotide was not designed as an appetite drug. Its appetite and craving effects are an on-target consequence of the receptor it activates.

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist with affinity for MC1R, MC3R, MC4R, and MC5R 1. The MC4R subtype is expressed densely in hypothalamic nuclei, including the paraventricular nucleus (PVN) and the arcuate nucleus, which are central regulators of both sexual motivation and food intake 2. When bremelanotide crosses the blood-brain barrier after subcutaneous injection, it activates MC4R in exactly the regions that simultaneously process appetite signals.

The MC4R Pathway: Sex Drive and Satiety in the Same Nucleus

The overlap is not a coincidence of anatomy. Endogenous melanocortin peptides such as alpha-MSH (derived from pro-opiomelanocortin, or POMC) suppress food intake via MC4R while also modulating dopaminergic reward circuits tied to sexual arousal 3. A synthetic MC4R agonist like bremelanotide therefore produces both intended effects (increased sexual desire) and predictable off-target effects (reduced appetite, altered food reward) from the same molecular event.

Animal models established this link years before Vyleesi reached Phase 3 trials. Cone et al. Demonstrated that MC4R-knockout mice develop hyperphagia and obesity, confirming that tonic MC4R signaling normally constrains caloric intake 4. Bremelanotide, by amplifying that signal acutely, temporarily tips the homeostatic balance toward satiety.

Receptor Selectivity and Why It Matters Clinically

Bremelanotide's binding profile is broader than the MC4R-selective compounds that were later developed as anti-obesity agents. Its affinity for MC3R, which modulates energy expenditure and adipocyte lipolysis, adds a secondary metabolic dimension 5. The clinical relevance is that appetite suppression with bremelanotide reflects simultaneous engagement of at least two distinct melanocortin receptor subtypes, not a single clean signal. This mechanistic breadth is why the appetite effect is real but not predictably dose-proportional in the same way it might be with a selective MC4R agonist.

What RECONNECT Actually Reported on Appetite and Nausea

The RECONNECT program consisted of two identically designed Phase 3, double-blind, placebo-controlled trials (Study 301 and Study 302) enrolling premenopausal women with HSDD. The pooled population was 1,267 participants, with 628 assigned to bremelanotide 1.75 mg and 639 to placebo 6.

Nausea: The Dominant Gastrointestinal Signal

Nausea was the most frequently reported adverse event in the bremelanotide arm. The published pooled data from RECONNECT show nausea in approximately 40% of bremelanotide participants versus 4% in the placebo group 6. Severity was predominantly mild to moderate. Median duration of nausea episodes was approximately 30 minutes, and nearly all episodes resolved within two hours of injection 7.

The FDA medical review for NDA 210557 notes that nausea was the primary driver of discontinuation in the bremelanotide arm, accounting for roughly 8% of withdrawals compared with approximately 2% in placebo 7. That gap is clinically consequential for prescribers counseling new patients.

Appetite Changes: Separate from Nausea

Reduced appetite and decreased food cravings were reported as distinct adverse events in the RECONNECT safety database, separate from nausea coding. The FDA prescribing information (PI) for Vyleesi lists decreased appetite as an adverse reaction occurring in at least 3% of treated participants 8. This rate, though lower than the nausea rate, represents a pharmacologically coherent signal rather than a secondary consequence of feeling nauseated.

Some participants reported not simply reduced hunger but a qualitative shift in food preferences, describing diminished craving for high-fat or high-calorie foods in the hours after injection. This pattern aligns with preclinical data showing MC4R activation preferentially reduces preference for palatable, energy-dense foods over standard chow in rodent models 9.

Duration and Reversibility

Both nausea and appetite suppression with bremelanotide are time-limited. The drug's plasma half-life is approximately 2.7 hours following subcutaneous administration 8. Appetite effects track closely with this pharmacokinetic curve. By 4 to 6 hours post-injection, most participants in RECONNECT had returned to baseline appetite. No cumulative or persistent appetite suppression was observed across repeated dosing cycles in the 52-week open-label safety extension study 10.

Mechanism Deep Dive: MC4R, the Hypothalamus, and Food Reward

Understanding how bremelanotide changes appetite requires a brief review of central melanocortin circuitry, because this is where the drug's action is most relevant.

POMC Neurons and the Arcuate Nucleus

POMC-expressing neurons in the arcuate nucleus release alpha-MSH, which binds MC4R on PVN neurons to suppress feeding. Bremelanotide mimics this endogenous signal with higher potency and longer receptor occupancy than alpha-MSH alone 2. The result is a transient but pronounced satiety signal that is proportional to the drug's bioavailability in CNS compartments.

AgRP (agouti-related peptide) neurons in the same arcuate region normally antagonize MC4R, driving hunger. Bremelanotide's agonist activity effectively overrides AgRP-mediated hunger signaling for the duration of plasma exposure 3.

Dopamine, Reward, and Craving Modulation

Cravings, particularly for specific food types, are processed partly through the mesolimbic dopamine system. MC4R activation modulates dopamine release in the nucleus accumbens 11. This is the same neural substrate through which bremelanotide is thought to enhance sexual desire. Its craving-modifying effects on food, therefore, are not categorically separate from its intended mechanism. They are the same mechanism expressed in an adjacent behavioral domain.

The practical clinical implication: patients who experience reduced food cravings after bremelanotide are not having an unusual reaction. They are experiencing predictable MC4R pharmacology in the mesolimbic system.

Comparing Bremelanotide to Flibanserin on Appetite Effects

Flibanserin (Addyi), the only other FDA-approved pharmacotherapy for HSDD in premenopausal women, acts through a completely different mechanism: 5-HT1A agonism, 5-HT2A antagonism, and weak dopamine D4 agonism 12. It does not engage melanocortin receptors.

Appetite suppression is not listed as an adverse event in the flibanserin prescribing information. Somnolence, dizziness, and hypotension dominate its side-effect profile 12.

The distinction matters for patient selection. A premenopausal woman with HSDD who is also trying to reduce caloric intake might find bremelanotide's transient appetite suppression a neutral-to-positive effect. A woman with a history of disordered eating or who has concerns about appetite alteration should be counseled specifically about this mechanism before starting bremelanotide.

Clinical Management: Reducing Nausea and Appetite Disruption

The FDA label for Vyleesi explicitly recommends consideration of an antiemetic before injection. Ondansetron 4 mg taken orally 30 to 60 minutes before bremelanotide administration is the most commonly used strategy in clinical practice and was used in RECONNECT's open-label extension for participants with significant nausea 8.

Timing the Injection Relative to Meals

Injecting bremelanotide on an empty stomach appears to worsen nausea in clinical reports, though the RECONNECT trials did not systematically vary feeding state. The FDA label advises against using bremelanotide more than once in 24 hours but does not specify fasting requirements 8. Prescribers at HealthRX generally advise patients to have a light meal 60 to 90 minutes before injection to reduce gastrointestinal sensitivity without blunting drug absorption meaningfully, as bremelanotide is absorbed subcutaneously and its Tmax is approximately 1 hour regardless of fed state 7.

Dose Frequency and Cumulative Appetite Effects

Because bremelanotide is dosed on an as-needed basis, not daily, cumulative appetite suppression does not develop in the way it might with a continuous-dosing regimen. The maximum approved frequency is once per 24 hours, and most clinical users inject the drug infrequently (2 to 4 times per month in the RECONNECT trial setting) 6. At that dosing pattern, total exposure is low enough that no meaningful effect on body weight was documented over 52 weeks in the open-label safety extension.

When to Reassess or Discontinue

Persistent nausea beyond 4 hours post-injection, vomiting requiring medical attention, or any sign of dehydration warrants reassessment. Patients who discontinue due to gastrointestinal intolerance should be evaluated for flibanserin candidacy if HSDD treatment is still indicated. The American College of Obstetricians and Gynecologists (ACOG) notes in its 2019 guidance that both available pharmacotherapies for HSDD have distinct tolerability profiles, and patient preference should guide selection 13.

Weight Changes Over Time: What the Long-Term Data Show

Short-term appetite suppression does not translate to sustained weight loss with bremelanotide. The RECONNECT 52-week open-label extension, covering 684 participants who continued bremelanotide use after the core trial period, showed no statistically significant change in mean body weight from baseline 10. Mean weight at baseline was approximately 76 kg across both studies, and no clinically meaningful deviation from that baseline was observed at any timepoint.

This contrasts sharply with dedicated MC4R pathway modulators developed for obesity. Setmelanotide (Imcivree), a selective MC4R agonist approved by the FDA in November 2020 for genetic obesity caused by POMC, PCSK1, or LEPR deficiency, produced mean weight loss of 25.6% at 52 weeks in its key trial (N=10 for POMC/PCSK1 deficiency cohort) 14. The difference in weight outcomes reflects the difference in dosing strategy: daily, chronic MC4R agonism versus infrequent, as-needed dosing. Bremelanotide's appetite effect is a transient pharmacodynamic event, not a sustained metabolic intervention.

Patient Counseling Points for Appetite and Craving Changes

Clinicians prescribing Vyleesi should address appetite changes directly during the informed consent and onboarding conversation. The following points cover the most common patient concerns.

"Will I lose weight on Vyleesi?"

Probably not, based on available data. Transient appetite suppression lasting 2 to 4 hours per dose, used 2 to 4 times per month, produces insufficient caloric deficit to generate meaningful weight change. The 52-week open-label extension data support this conclusion 10.

"Why do I lose interest in food after my injection?"

MC4R activation in the hypothalamic PVN sends a satiety signal that overrides normal hunger cues for the duration of drug exposure. This is the same receptor the drug uses to increase sexual desire. Both effects come from the same molecular event, and both resolve as the drug clears 2.

"Is the appetite change dangerous?"

In otherwise healthy premenopausal women without a history of disordered eating, transient appetite suppression for 2 to 4 hours carries no documented clinical risk. Women with a current or historical eating disorder should discuss this effect specifically with their prescribing clinician before starting bremelanotide, as even transient appetite cues may interact with underlying patterns 15.

"Will I crave different foods?"

Some patients report reduced craving for high-fat foods specifically, consistent with preclinical data on MC4R's role in modulating hedonic feeding 9. This effect is not universal, has not been systematically quantified in clinical trials, and should be characterized as possible rather than expected.

Special Populations: Considerations Beyond the Standard Label

Patients With Obesity (BMI <40 kg/m2)

RECONNECT did not stratify safety outcomes by BMI, and the FDA label does not include BMI-specific guidance on appetite effects. Body weight does not appear to predict nausea or appetite suppression severity based on available data. Dose adjustment is not required for patients with obesity 8.

Concurrent GLP-1 Receptor Agonist Use

No formal pharmacokinetic or pharmacodynamic interaction studies between bremelanotide and GLP-1 receptor agonists (such as semaglutide or liraglutide) have been published. Both drug classes suppress appetite through distinct central and peripheral mechanisms. GLP-1 receptor agonists act primarily through vagal afferents and brainstem GLP-1R, while bremelanotide acts through hypothalamic MC4R 16. Additive nausea is a theoretical concern given overlapping gastrointestinal adverse effect profiles. Prescribers should discuss this combination explicitly with patients using both classes concurrently and consider spacing injections to avoid overlapping peak plasma concentrations.

Patients With a History of Disordered Eating

Appetite-modifying drugs require particular care in this population. The melanocortin system interacts with neural circuits that are dysregulated in anorexia nervosa and bulimia nervosa 15. Bremelanotide is not contraindicated in women with a history of eating disorders, but prescribers should screen for active disordered eating before prescribing, document the discussion, and monitor for changes in eating behavior during use.

Summary of Key Clinical Data Points

The table below consolidates the primary safety signals relevant to appetite and cravings from the RECONNECT program and FDA review documents.

| Outcome | Bremelanotide 1.75 mg | Placebo | Source | |---|---|---|---| | Nausea (any grade) | ~40% | ~4% | RECONNECT pooled [6] | | Discontinuation due to nausea | ~8% | ~2% | FDA Medical Review [7] | | Decreased appetite (reported AE) | >3% | Not reported separately | FDA PI [8] | | Median nausea duration | ~30 minutes | N/A | FDA Medical Review [7] | | Weight change at 52 weeks | No significant change | No significant change | OL extension [10] |